H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.01 CNY -4.3% Market Closed
Market Cap: 19.8B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hubei Biocause Pharmaceutical Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Retained Earnings
ÂĄ5.2B
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
48%
China Life Insurance Co Ltd
SSE:601628
Retained Earnings
ÂĄ494.7B
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
11%
Ping An Insurance Group Co of China Ltd
SSE:601318
Retained Earnings
ÂĄ812.2B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
21%
New China Life Insurance Company Ltd
SSE:601336
Retained Earnings
ÂĄ137.5B
CAGR 3-Years
25%
CAGR 5-Years
23%
CAGR 10-Years
24%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Retained Earnings
ÂĄ42.6B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
19.8B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Intrinsic Value
4.79 CNY
Undervaluation 16%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Retained Earnings?
Retained Earnings
5.2B CNY

Based on the financial report for Jun 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Retained Earnings amounts to 5.2B CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
48%

Over the last year, the Retained Earnings growth was -14%. The average annual Retained Earnings growth rates for Hubei Biocause Pharmaceutical Co Ltd have been -6% over the past three years , and 48% over the past ten years .

Back to Top